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A qarhalie hicudin peplidr anclog eorrcqndin@ tcr h”-acrtyl (D.Ph@, ArgY’(CCXXl~*, Ol~jd~sulftp hirudW** (P791 ww Syn\h&xd, Gem- 
par&u kin& r~udic* rhawed the1 whilcrecembinclnt hlrudin (ElVZY iarr &w-light b~nd~n~~nhib~tnr, P7Q krhevrr ar #elrlsicrileormgrtirivc inhibitor 
of human a-thrumbin (Kp3.7&tB,Jx 10”le Mf nnd bovine a-rhtembin (13~~0.7 x IOSq M). P79 nhewcd saturable inhihitian of plarmn APTT. 
The P,‘rubrite ofP7Yif irartcric with the glycinc rr&duenf lhc ntrtunl thrembin subdtrrtc Rbrinogcn, bul ix prtl~ecllyricdlly nrnblc dur IO the inearpo- 
ralien af a kctamcrhylcne pnrudepcplidc band. The model a&vr sita-directed tripcptidc [g.Phc.Prtl-ArpY’(~gCrl,)CH,CaOCH,, P79L] eor- 
rcrpanding IB the nmina lcrminel of P79 rlrs hind% conrptitivrly fo the octivt! nita af a4hrambin and inhibited lhc pratcalyrin of a tripirptidyi 
substrate with n K,= 17,Q & 2. I lrwI (human] und IO.3 & 3.6 rrM (bovine) a-rhrambin. NMR exprimenlx lndlcnted that P79L tend the esrroponding 
trmino terminal rcridues ST 879 aceeupy a mutually cxelrrrive binding sire on bevinE a-rhrambin while the crrbxyl terminal tail of the Wcr adapts 
P &nilrtr bound cenformatian DJ the fragment hirudin *‘=a which in kntrwn w inrernct with the ‘anian exasito. Taken ragether these results provide 
cancluriivc evidcnec that flu? high rntithrembin uctivity of h%uxlyl[D+he+‘, ArgYVXKX,~P, Gl~jdasulfo hirudin 4~ xtcmr from rhs concurrent 
intcrrction with the catalytic site und the puWve*nnion CXOI/IC Ihrurr@ irr rrqxetive NH,- und CBBH-tcrmin,rl rfeognirian nhca, 
Hirudin nnelog: Thrombin inhibitor: Reudepcptide; Active site; Exesite 
1. INTRODUCTIO’N 
Thrombin is the principal enzyme that acts in concert 
with other activated factors of the hemocoagulative 
system to regulate clot formation in response to 
vascular tissue clamage. Although cu.thrombin ishighly 
specific toward fibrinogen as its natural substrate, its 
szruccurai homology to other serine proteases may 
preclude the development of specific and effective 
active-site directed inhibitors which could be useful to 
treat thrombotic disorders, Indeed a large number of 
synthetic or substratemrelated inhibitors have been 
reported [l], but most of them suffer from vaeious 
drawbacks such as low potency, poor selectivity or 
potential toxicity. The most potent inhibitor of M- 
thrombin known is hirudin [2,3], a ‘7 kDa family of 
isoproteins isolated from the glandular extracts of the 
leech Wirudo medicinalis. I-Iirudin forms a high affinity 
non-covalent stoichiometric omplex with a-thrombin 
(Ki = 10’” to lo- *’ M), but does not inhibit trypsin, 
kaltikrein or other hcmocoagulant swine proteases (41. 
It is now known that the high affinity is due to the 
multiple interactions of hirudin with cu-thrombin while 
the specificity stems from the interaction with at least 
one complementary binding site that is unique to CY- 
thrombin [5,6]. This putative ‘anion’ exosite may also 
be required for fibrinogen binding. 
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We have previously demonstrated that desulfo- 
hirudin’5’65 corresponding to the carboxyl termincrl 
fragment of recombinant hirudin variant 1 (r-HVl) can 
inhibit the amidolytic activity of human cr-thrombin 
towards synthetic substrates [7]. Although the inhibi- 
tion by this native fragment was weak and the 
mechanism partially competitive compared to r- 
hirudin, a modification of the NHZ-terminal residues 
by substituting D-Phe and Arg in positions 45 and 47 
respectively, afforded an inhibitor with a Ki = 2.8 ZL 
0.9 nM against human a-thrombin. The enhancement 
of enzyme affinity compared to the corresponding 
native fragment was attributed to favored interaction 
with the S1 and S3 subsites of the catalytic center while 
the G-terminal region comprising residues 55-65 could 
serve as an anchor that binds to the putative ‘anion’ 
exosite. 
tlbbreviu&ms: NOE, nuclear Qvsrhaussr enhancement; Boc-AOGO, 
SN-ten-butyloxycarbonyl-4-oxo-8.tosyl guanidinooctanoic acid; 
TFA, trifluoroacetic acid; AMC, ‘I-amino-l-methyl coumarin; 
APTT, activated partial thromboplastin time 
In this communication, we report that this model was 
used to obtain a new class of reversible inhibitors pro- 
totyped by P49 (Pig. 1) with high enzyme affinity and 
whose in vitro plasma antithrombin activity approaches 
the level of r-hirudin despite the drastically reduced 
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K’.AceryllD~Pk$“,hrp 9(c61e~l)“S,~i~“~dc~ulr~ hiruJhP”*! 
was nynthtsiacd on an Apptietl t3ioxywIrmr 43OA peplidc rymheolxrr 
as daaeribcd previously (7). The synthetic nrnlnti acid ~43oe&Arg 
S[COCH#X-i&XXX~ (Boc4OGO) was prepared by a muliixrcp 
procedure that will be rcportcd in dciail clnewhcrc. This novel W*- 
proreercd &cIomcthylrnc amino rcid was obtained enan~lomrrienlly 
pure, [&’ m + 18 (c = 2,McOH), and was Incorporated into the 
polymer~bound pcptidc using a srandnrd coupling procedure 
mediated by dicyclahcxylcarbodiimidc/~-~~y~lro~yben~o~ria~o~c. The
Crude peptide obtained following hydrogen fluoride treatment was 
purified to homogeneity in OIIC rep using rcvcrx phase 
chramatography 011 n Vydac oc~adccyl silica glass column as describe 
cd previously [7]. The pcpiidr was more rhan 98% pure as judged by 
analyticat HPLC on a Vydac 5 arm, Cl8 column using UV dctcction 
81 215 nm, AltcrnaIivcly, Boc-AOGO could first be mclhylrrcd 
using diazomcthanc, dcblockcd with rrifluoroncciic ncid and sub* 
ncquenlly incorporated as the Iripeptidc l\r’Xbz-(D)-Phc&o. 
Arg(Tos)S[COCH~]CHrCOOCH~ using srandard solutinn methods 
and purification on silica gel. The blocked tripclxide was [rented with 
HF as described above and lyophiliscd. For accrylation, Ihc crude 
peptide was rcdissolvcd in I ml of cold sodium phosphate buffer, ~1.1 
7.5, and treated with IGO pl of acetic anhydridc and the mixture 
maintained a1 O°C for one hour [B]. The solution was dilufed with 
water, frozen in a dry ice/acetone baIh and lyophilircd. The producI 
was purified as described above. The resulting tripcptidc is designated 
as P79L (Fig. I), Amino acid analysis was performed on a Beckman 
model 6300 amino acid analyzer following hydrolysis on a Waters 
p a V,,,cIw- h)(I -15) 
k? 
(2) 
The anIicuagulant activity of r-HV2 and synthetic peprides was 
cvaluatcd spcc~ropl~otometrically *rn a Varinn DMS 90 spcc. 
trophotometcr nI 405 nm. 5Olrl of I,ccansIituted titrated plasma con. 
trol was mixed with 50 jcl of thromboplastin riolution 81 37OC, This 
solution was trcnted wiIh either 2OOctl of Tris-#Cl buffer, pi-l 7.8 
containinwO,l M NaCI, 0.1% PEG 6OOO or variable conccntraIions 
of inhibitor in the same buffer. The clotting time \vas recorded 
following rccalcificarion with 100 al of 25 mM CaCIz solution. The 




Fig, 1. Chemical structure of N”-acetyl[(D)-Phe45,Arg~(COCH2)4’,GlyJ8]desulfo hirudin 45-65 (P791 and P79L. The amino acids represented by 
the single letter code in P79 comprise the spacer that links the components of the catalytic site (left) and the auxiliary ‘anion’ exosite (right). 
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In the previaur paper in thin serieru we rcporrcd that 
the acetyl;rred enrbaxyl wminnl hirudin fra~mcnt corn= 
prising residues 45-65 inhibits bath the fibrinsgen clot- 
ting activity of a-thrambin and the amidelyric activity 
of the enzyme reward tripeptidyl substrata (KI = I IO % 
30 nM, human cr-rhrombin). This result is at variance 
with 0th~ reports [15] and with recent X-ray structure 
determinariono f the esmplex between human cy- 
thrombin and either r-HV2-Lys’7 [S\ or r-I-IV1 (61 
which clearly demonstrate char hirudin binds in the 
region of the catalytic cleft through its NHa-terminal 
three residues. By inference, deletion of residues l-44 
could expose new recognitive elements within the 
thrombin substrate-like scqucncc onsisting of residues 
Thr-Pro-Lys-Pro whose spatial ciispositior1 pc#mirs in- 
teraction with the catalytic site and substitute for the 
native NHz-terminal residues of intact hirudin, albeit 
not as effectively, The probability of this mechanism is 
corroborated by our previous observation showing chat 
substituting Th? and LysJ7 by (D)Phe and Arg, 
respectively, confers potent and competitive inhibitory 
activity (P53, Ki = 2.5 f 0.9 x lo”‘, human N- 
thrombin). The present results demonstrate that a 
significant improvement in potency and stability is 
achieved by appropriate modification of the scissile 
bond and structure of the Pi subsite of P53. 
Reasoning by analogy with fibrinogen, which incor- 
porates a glycine residue at Pi, we have successfully in- 
corporated a ketomethylene surrogate [16] into P53 in 
order to mimic the scissile hrg-Gly peptide bond in the 
natural substrate fibrinogen. This new structural 
prototype (P79) NW-acetyl[D-Phe’5,Arg~(COCH~)4’, 
Gly4”]desulfo hirudin 45-6s (Fig. 1) competitively in- 
hibits the proteolysis of the tripeptidyl substrate Tos- 
Gly-Pro-Arg-amc with Ki = 3.7 f 0.3 X iO_” M 
(Fig. 2A) and 1.8 & 0.7 x IO-” M for human and 
bovine cu-thrombins, respectively. These values repre- 
sent up to 450.fold increased affinity for the enzyme 
compared to the original native fragment W-acetyl 
dcsulfo hirudin45-B5 described previously [7], but still 
approximately lOOO-fold lower than intact recombinant 
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Fig. 2. (A) Dixon plot of the inhibition of human rr-thrambin- 
mcdiarcd hydrolysis of Tos-Gly-Pro-Arg&NZ by W’-acctyl[(D). 
PlreJ”,AryY(CGC~lr)“?,Olydnldcrulfo hiruclin”‘“’ (P79). The K,,, for 
fhc subx~rarc was dctcrmined to be 3.8 nnd 5.5 pM for human and 
bovine b.thrombin, rcspcctivcly, Assays were performed as described 
in the cxpcrimcntal section in the presence of 2,s (is), 3.5 (O), S (4), 
IO (A) and 20 gM (0) substrate. The calculated Ki values for human 
and bovine m-thrombins were: P79, 3.7 r 0.3 x 10*‘” M and l-8 k 
0.7 x 10” M; P79L, 17,9 f 2,1 x 1O’6 and IO03 + 3.6 x W6 M. 
(B) Slaw-binding inhibition of human cr-thrombin by r-hirudin (r- 
HV2). The condhicns were as described under the experimental 
section in 100 mM Tris buffer, pH 7.8 containing IO0 mM NaCI. 
Enzyme and substrate concentrations were fixed at 20 pM and 
25 pM, rcspectivcly. The determined association and dissociation rate 
constants were 1.9 f 0,2 x IO* M*‘*s-’ and 5.3 f 1.4 x lo-” s-’ 
respectively with a corresponding KI = 2,8 f 0.7 x IO-” M. 
tions r-HV2 behaved as a slow tight-binding inhibitor 
WI = 0.28 A 0.07 PM) (Fig. 2A) in agreement with 
previous studies [8,13] that have implicated a probable 
two-step mechanism for hirudin binding. In contrast o 
hirudin, P79 did not display tight binding inhibition 
and the progress curves for product formation were 
linear over time. Despite the drastically reduced size 
compared to hirudin, amidolytic experiments using 
trypsin showed no inhibition up to concentrations of 
50 ,&I of P79, thus retaining the sp&5ficity conferred 
by the fibrinogen recognition site as is the case with in- 
tact hirudin. Expectedly, incubation of P79 with 
human a-thrombin over 24 h at 37°C resulted in no 
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0bs~~vRhlG ptalrolynlr in contrwt 10 Its pr~~~~It~~ W- 
acctylffl~Ph~~“,Ar$‘~~~~~lf~ l lrudir+“~ (P53) which 
was slowly hydrolyzed on tha earboxyl sidc of ArgJP 
[7]. Since thrombinnm~dl~t~d protoolystr of PS3 was 
not Q factor in the time frnrn~ of kinstle mcwuvzmaw 
\vc conlrlude that the enhanced etXymc wffinlty t3r P78 
eainperctd CQ Pf3 coulrf be a ~~ns~qu~nc~ of a prcl’erred 
~~~forrn~tion~l efft8zt at Pi or @atCr ~ol~ri~ati~~ of 
the kstsnet WWJ rhrr amide function in the catalytic 
site. Fig. 3 shows that P79 prolongs tkc activated par- 
tial thramboplaxrin time of normi human plasma in a 
concentration dcpandenr manner. Comparcd to 
hirudin, both P79 and 1853 CWW. a saturable effect on 
APTT, However, the clottin& time at the saturating 
level of P76 was more than double that of P53 over the 
same concentration ranging from 0.2 to 0.6 &400 pl, 
The inreracrion of thrombin with fhe active sire 
directed component of P79 was investigated by 
evaluating the inhibitory activity and identifying the 
enzymeGnduced broadening of the: NMR proton 
resonances of the model tripeptidc IV’Wcryl-(D)-Pheg 
Pro-Arg*(COCHa)CH$ZOOCWJ which is designated 
P79L and is srructurally related to the active site 
alkylating agent PPACK [17]. P79L inhibited the 
hydrolysis of rhc fluorogenic substrate Tos-Gly-Pro- 
Arg=amc msdiarcd by human cu-thrombin competitively 
with a Ki = 17.9 f 2.1 PM but was slightly more effec- 
tive against he bovine isozyme (KI = 10.3 * 3.6,uM) 
suggesting subtle structural differences also in the 
respective active site of thcsc two enzymes. The se- 
quence denoted by amino acids using the single letter 
code in Fig. 1 represents the region that we have 
designated as the ‘spacer’ required to bridge two 
remote binding sites [7]. Accordingly, the N-terminal 
residues to the left of the spacer can interact with the 
catalytic site while the C-terminal residues to the right 
of the spacer have recognitive lements characteristic of 
the fibrinogen groove or exosite [17, I$]. The 
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Fig. 3. Inhibition of activated partial thromboplastin time by rHV2 
(CJ), P79 (0) and P53 (A). The anticoagulant activity was measured 
as described in the methods using normal human plasma. Each point 
is the mean of three determinations. 
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~~n~r~~~~i~ inhibitary mxlvity, Ws have prcvlously 
found that thcr fr~~~~~~ ~~r~~~~~n~~~~ ta iV=ace~yl 
lWIdinr”“d” doubles the fibrinoytcn clotting time of 
humgtn sYlrhFombin 81 O,? &l, whliar the lnhiblrary 
di~$~~~~ti~fl ccanWux fsr the frr~mcnt ~~rr~~p~ndin$ 
f61 hirudin’“4z haa been rlrporrod ccz ba C.I.3 /ri%i [SP]. Ur- 
ing there valrien, the exgccted KD ~8 hirudin would be 
in the! order of 0,2 pM which is in agritremcnt with the 
exparimencally determined vnluc of 0,28 $ 0.67 pM 
found in this study. On the other hand, the determined 
& value of P79 (0,37 L a,03 nM) dcviatcs lightly from 
the expecred value af 13 pM if the inhibitory dissoeia- 
tion conetflnt were the! oimple groduetr of the individual 
eomponentri as is the case with hirudin. This divergence 
could reflect the different binding mode of P79 with 
rhrambin compared to intact hirudin whose 
hydrophobic NHZ-terminal residues interact with the 
putative apolar binding site in B direction opposite t8 
what would bc expected of a substrate and without oc- 
cupying the specificity pocket [S&S]. Moreover, the 
&residue sequence that scparutes the catalytic sire and 
‘anion’ exositc in P79 may not be optimum compared 
to the large but compact conformationally-defined core 
of hirudin [20,21]. However the short spacer of P79 
could be modified to further enhance nzyme affinity, 
Fig, 4A shows the NMR proton spectrum of the 
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Fig 4. NMR spectra of the NH and the aromatic region of P79L 
5 mM in the absence (A) and in the presence (B) of 0.3 mM of bovine 
a-thrombin. Spectrum C shows the same region in the presence of 
0.3 mM thrombin and 0.6 mM P79, The NH proton resonances of
D-Phe and Arg are at 8,4 and 8.17 ppm, respectively, while the psaks 
between 7.2-7.5 ppm are the ring proton resonances of D.Phe. Note 
that only one of the NH doublets (indicated by the arrows) of Arg4’ 
is broadened by thrombin binding (middle panel). This effect, 
together with the line broadening of the aromatic ring protons, was 
reversed upon addition of the bifunctional inhibitor, P79 (C). 
Prs-Arg nmide bond af rhe tripepridle EXists In an ectu#t 
~o~~il~tt~n Qf C/S and mm ts~rn~r~ ax rel”leerccl bythe 
s~li~~tn~ of rhe NH r~s~n~n~~s @toclbtrfr ~~d~~bt~~s) of 
R-Bhs (Wt ppm$ and AJO (1.17 ppm). In Fh@ prascncc 
of thrsmbin (Fig. #I), only ono of thtl sonftxmerte b 
NH prertons cat Arg was braadtned by a=rhrcsnbin, 
whjlc the dN=+! pretan af the DPhe rexiduc wns unaf- 
t&ted. Therefore whik only rhe amide proton a? rhr 
arginine residue! is impticared in binding to Ihrombin, 
only one conformt~rionrrl isomer is comparibls wirh Ptis 
binding sire, The most pranaunced line broadenin was 
observed for the resonance signals corresponding to the 
aromatic ring protons of (D)=Phc 1s illustrated in 
Fig, 4% Hc)wever, addition of P79 (0.6 mM) Co a 
preformed camplex of rhrambin (8,3 mM) with P79L 
(S mM) was found co reverse ttrc thrombin-induced line 
broadening (Fig. 4C). This suggests fhat the 
NHx-terminal moiety of 879 interacts with the same 
binding site as P79t, which would be expected to be the 
apoler region of the catalytic cleft due co its homology 
wirh the active sire inhibitor PPACK. 
Using NMR transferred NGE measurements, we 
have found rhat residues Glue’ co Gin” in a peptide 
fragment corresponding 10 desulfo hirudin”‘*‘s form a 
helical structure when bound to bovine cx-rhrombin 
(131. The resulting conformation orients the non-polar 
side chains of residues Phe’*, I@, Pro60, Tyr43 and 
Leu@ in a characterisric hydrophobic luster in contact 
with thrombin. The NOES for this structure of 
hirudin5”6s were (hose between the c&H proton of 
GIu*’ and the NH and side chain protons of Leu6j and 
bctwecn the side chain protons of residues Phe”, Ile”, 
2 
Fig. 5. A portion of the two.dimensional NOE spectrum of P79 
(3 mM) in the presence of bovine cu-thrombin (0.2 mM), The labels 
indicate the proton pairs that give rise to the particular NOE 
crossaeakls). The NOES between residues Glu6’ and LeuM 
B 
(61&64@,k’and 61a/64d), together with the NOE between the cuCH 
proton of GIL?’ and the NH proton of Leu6’ (not shown), indicate 
that residues Glub’ through Leua form a helical conformation when 
P79 binds to thrombin. Other observed NOEs not displayed in the 
spectrum in&de those between the 6CH protons of Ph@” and ihe 
KH protons of Ile”, between the 7CH and the 6CH protons of lies’ 
and the GCH protons of Tyr 63, between&H protons of Pro”‘and the 
BCH protons of Tyr”3 and between the KH protons of ‘Tyr63 and 
GCH protons of Leu”. 
Prodi”‘, Tyrbr and Lao”, Stmtkr rr8mrfcrrrd NCX% w@rP 
WIW abxerved within rsrtdues Phcr” ttl‘ Qlnar of the In= 
hibitar P79 (Ftg. S), ~u~~c~~in~ rhar the CZ+HT&I~I par= 
tian at’ 879 binds to lhrombtn in a atmilnr 
cont’cxmarisn aji rher of rha gep6ide Iraamenf 
hirudin’“““, Furrhcrmore, all. of rhcr resatved 
rrronances at” rizsiduer Aspff w Qln6’ in P79 ara nf- 
fcc~ed by Ehrombin binding to a simttar extenr ax 
hirndin’“*bs (data nglf shown), Thcrc results indicate 
rhar resiclucs A# through CX? in P79 inreract with 
the thrombin exosire airnilar to rhe pepride fragmenr 
derived from the C-rerminat region, Taken tagether, 
rhc abeve results provide conclusive vidence thar P79 
behaves as a bifunctional inhibitor thar interaaa eon- 
currendy wirh the earstytic oirc and ‘anion’ exoaitc of 
rhrsmbin analogous to hirudin. 
rJ”-acetyl(B-Phe*~~Arg~(~~~H~)~~,Gly~n~desullo 
hirudin”S”OS remains the most potent inhibitor of CT- 
rhrombin reported to date other rhan hirudin itself. Fhc 
enhanced affiniry for cu-thrombin compared to rlre 
native congener IV-aceryt desulfo hirudin”“bs, tha 
analog N”.acetyl[B-Phe’“,Arg”]deslllfo hirudin45-6f 
(71 or analogous hirulogs [22] can be aru-ibured irectly 
to (1) grearcr primary spccificiry and secondary 
recognition at SI and SB conferred by ArgJ’ and D- 
Phc?, respectively al;d (2) the incorporation of a 
ketomcthylcne pseudopeptide bond which is isosrcric 
with glpcine in the scissilc bond of the nacueal 
substrate. Inclusion af the keromethylcnc function con- 
fers complete enzymatic resistance toward cr.thronbin 
and would also be cxpccccd to increase the clecrrophilic 
properties of the carbon atom bearing the ketone 
group. Previously described hirulogs have been 
designated as non-competitive thrombin inhibitors 
[22]. It is interesting to note rhat the inhibition of cy- 
thrombin by P79 is purely competirive with respect o 
the tripeptidyl substrate Tos-Gly-Pro-Arg-amc, but 
that the presence of a proline residue at P; has a 
modulating effect on rhe mechanism of inhibition 171. 
Furthermore, the polyglycine spacer characteristic of 
hirulogs may contribute a subtle qualitatively different 
mode of interaction with thrombin that could affect Ihe 
active site. A derailed structural analysis is in progress 
for a better understanding of the mode of binding of 
this new class of thrombin inhibitors. 
Acknowledgonenrs: We are indebted to Dr Michael Mancini, Mr 
Jean Lefebvre and MS Debra Munn for expert technical assistance, 
mass spectral analysis and peptide synthesis, 
REFERENCES 
[I] Sttirzebecher, J. (:954) in: The Thrombin, Vol. ! (Macho!& 
R. ed.), CRC Press, Chap. 7, pp. 131-160. 
[2] Markwardt, I;. (1970) Methods Enzymol. 19, 924-932. 
[3] Bagdy, D., Barabas, E., Graf, L., Petersen, T.E. and 
Magnusson, S. (1976) Methods Enzymol. 25, 669-678. 
51 
Volume 2#2. number ! FEB$ LETTERS Apri l  1991 
[4] Seem6ller, U., Dod|, J,, Fink. F~. And Fth=. I1. (191t6i n: 
Prolein~,¢ inhtbtlOr~ (B~trreIK A.J,, Salve~.,en. G, ed~) Chirp. it. 
r~hevter, 
($] Rydd, T.J',, P, avlehandrltn, K.G,, Tl#lin~ky, A,, Bode, W,, 
kluber, k.. Roi(t¢lt. C:, ,rod Fen(o,~, J,W, I1 (1990) Science 249, 
=11=210, 
[6} Gruiter. M.G., Pde~zle, J.P,, gahu¢l, J., Gros~¢nb~:her, H,. 
Bode, W,, Hor~le~nlt¢, J and $~o~e. S. (1990) Eh|BO J, 9, 
2161-2],65. 
I?} DiMaio, J,, Gibh,% B,, k-tunn, D,. Lefehvre, J,. Hi, F. and 
Konl~ht, Y, (1990) J, Biol. Chem, 265. ~169~=2170~. 
18] W=dlaee, A.,, Dennt~, $,. Hof~lee~*|e, .1, and S~one, $.R. (1989} 
Biochemistry 2it, 10079~100#4 
19] IMSL (19~?) IMSL Llbrnry R~feren¢~ M~n.~l, 91h ¢di(Ion 
verflon I,O, IM$1, Hou~ion, 
[10) ~eBel, I.H~ (19"/:~) in: Enxyme Kinefl¢:~*. Chap, ~, John Wil=y, 
New York, 
[11] CIm, $, (1976) Bioehem, Phanrm¢ol. 2~, 2695-2702, 
[12] Willi~tm~. J,W, nnd Morrison, J,F. (1979) Me|hods Enzymol, 
63, 4~t7-46"/. 
i l l}  $(one, S.R, and Hot'steenllc, J, (19~6) Bio~l~emislry 25, 
4622-4628, 
1141 Ni, F., Konhht. Y, rand ~Jehcralm, H.^, (1990) Blod~eml+~r:t 29.
4479~44~. 
II:~] Kr~len.n~ky, J.L, nl~d bhto, S,J,T. (l?#'/l FI~B~ L¢Ii. 211, 
10=16. 
1161 AlmquM, R,O,, Chao. W.R,. Ellis, M.F., ~tnd Jel~n~on, H.L. 
(1980) J, MOd Chem. 2L 139Z. 
ll?] Bode, W.. M~yr, I,, Mmml~nn, U., Hither, R.. $lo.e, $,R, ~.d 
Hoflleenlle. J. (19~9) EMBO J. 8, ;1467-;14"R[, 
[1#] ChanJ, J,Y.C., Hi#l, P.K., Rink, H., Dennis, ~. ~nd 
$¢l~l~eppi, J,M, (1~90) FEB$ L¢II. 261,287~290, 
[19] Ch~tnllt, .I'.Y.C. $¢hl~eppt, J.M. =md $iort¢, $,R. (1990) FEB$ 
[,ell. 260. 20P-2|2, 
[20) Clore, G.M., $~kumttrml, D,K., NIlllc~, M., Zarbnek, J. and 
<3ronenborn, A,ht, (i987) EMBO J, 6, $29~$~17, 
[21J P'olker~, P.J.M., Clore, O,hl,, Drll¢oll, P,C,, Dod¢= J., 
K6hler, $, and Gronenborn, A.M, (1989) Bloeheml~lry 28, 
2601-261'7, 
[22) M~r~ll=tnore, J,M,. Bourdon. P,, J~blonsky, J,, 
R,madmndr~tn, K.L, =tad Fenton, J,W. !1 (1990) Bioeherni~lry 
29, 7095-7101, 
52 
